Seiji Niho

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +12

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Journal of Clinical Oncology · 2018 · 436 citations

Medicine, Oncology, Pharmacology +12

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

Shigeki Umemura, Sachiyo Mimaki, Hideki Makinoshima et al. · Journal of Thoracic Oncology · 2014 · 219 citations · Full text

Medicine, Genetics, Oncology +17

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara et al. · Lung Cancer · 2012 · 214 citations · Full text

Medicine, Oncology, Pharmacology +12

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh et al. · The Lancet Oncology · 2020 · 209 citations

Medicine, Oncology, Metastasis +11